|
|
Volumn 86, Issue 10, 2002, Pages 1662-1664
|
|
Granisetron vs ondansetron: Is it a question of duration of 5-HT3 receptor blockade? [2] (multiple letters)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIEMETIC AGENT;
ANTINEOPLASTIC AGENT;
CISPLATIN;
CYCLOPHOSPHAMIDE;
GRANISETRON;
ONDANSETRON;
SEROTONIN 3 ANTAGONIST;
CANCER CHEMOTHERAPY;
CANCER PATIENT;
CHEMOTHERAPY INDUCED EMESIS;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CROSSOVER PROCEDURE;
DRUG EFFICACY;
DRUG INFUSION;
HUMAN;
LETTER;
PHARMACODYNAMICS;
PRIORITY JOURNAL;
RECEPTOR BLOCKING;
SEROTONINERGIC SYSTEM;
VOMITING;
AFFERENT PATHWAYS;
ANTIEMETICS;
ANTINEOPLASTIC AGENTS;
CISPLATIN;
CLINICAL TRIALS;
CROSS-OVER STUDIES;
DOSE-RESPONSE RELATIONSHIP, DRUG;
GRANISETRON;
HALF-LIFE;
HUMANS;
ONDANSETRON;
RECEPTORS, SEROTONIN;
RECEPTORS, SEROTONIN, 5-HT3;
RESEARCH DESIGN;
SEROTONIN ANTAGONISTS;
VAGUS NERVE;
VOMITING;
VOMITING, ANTICIPATORY;
|
|
EID: 0037141570
PISSN: 00070920
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.bjc.6600313 Document Type: Letter |
|
Times cited : (15)
|
|
References (0)
|